Article
Oncology
Hao Zhang, Zhiyang Chen, Zeyu Wang, Ziyu Dai, Zhengang Hu, Xun Zhang, Min Hu, Zhixiong Liu, Quan Cheng
Summary: APOBEC3B expression level is high in advanced gliomas and other cancer types, correlating with poorer prognosis. It can impact patient survival and is significantly associated with infiltrating immune and stromal cell types in the tumor microenvironment. Additionally, APOBEC3B is involved in tumor mutation and regulation of oncogenic genes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Guihua Tang, Liming Tan, Hao Yuan, Wen Yin
Summary: This study evaluated the glycosylation modification patterns of low-grade gliomas (LGGs) and developed a glycosylation score to quantify the glycosylation modification patterns. Two distinct glycosylation patterns were identified, with different prognosis, metabolism, and immune microenvironment features. The glycosylation score was found to be a reliable and independent prognostic index and influenced the response to immunotherapy, chemotherapy, or targeted therapy, providing insights into personalized therapy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Qijun Xie, Xianlong Huang, Wu Huang, Fang Liu
Summary: PD-L2 is a prognostic biomarker for patients with lower-grade gliomas, predicting prognosis, immune infiltration, and therapeutic sensitivity. The study found that PD-L2 is upregulated and strongly correlated with the macrophage biomarker CD68 in gliomas.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Rui Tao, Ruoyu Huang, Jingchen Yang, Jiangfei Wang, Kuanyu Wang
Summary: Cholesterol metabolism is significantly associated with clinicopathologic features and genomic alterations of lower-grade gliomas (LGGs). It plays a crucial role in immunosuppression of LGGs by promoting macrophages polarization and T cell exhaustion. Cholesterol metabolism is an independent prognostic indicator for LGG patients and can be used to predict their survival rate.
Article
Immunology
Yirui Kuang, Bincan Jiang, Hecheng Zhu, Yi Zhou, Haoxuan Huang, Can Li, Wenlong Zhang, Xuewen Li, Yudong Cao
Summary: We identified ICD-related genes and divided glioma patients into two subtypes based on gene expression profiles. The high ICD subtype showed worse prognosis, higher immune infiltration, and more active immune response. We also developed a prognostic signature and confirmed the importance of EIF2AK3 gene in glioma.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Siliang Chen, Shuxin Zhang, Zhihao Wang, Junhong Li, Yunbo Yuan, Tengfei Li, Mingrong Zuo, Wentao Feng, Wenhao Li, Mina Chen, Yanhui Liu
Summary: This study examines the relationship between the expression of purine metabolism-related genes (PuMGs) and the clinicopathological features and immune landscape of glioma. The results indicate that the expression level of PuMGs is associated with the aggressiveness and prognosis of glioma, and can be used to predict therapy response and prognosis in patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Zhile Wang, Fucun Xie, Yijun Wu, Li Wang, Yi Bai, Junyu Long, Xiang Wang
Summary: The study showed a close correlation between high ICI scores and high TMB values, with ICI scores serving as reliable prognostic predictors. The predictive model established demonstrated significant superiority among glioma patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Xu Zhao, Yuzhu Wang, Jing Li, Fengyi Qu, Xing Fu, Siqi Liu, Xuan Wang, Yuchen Xie, Xiaozhi Zhang
Summary: The study found that RFC2 is widely overexpressed in diffuse lower-grade gliomas (LGG) as well as other cancers, and is closely related to clinicopathological features and prognosis. Additionally, RFC2 is positively associated with immune cell infiltration and immune checkpoint gene levels in LGG, and plays an oncogenic role in LGG progression.
SCIENTIFIC REPORTS
(2022)
Article
Genetics & Heredity
Hua Zhu, Xinyao Hu, Lijuan Gu, Zhihong Jian, Liqin Li, Siping Hu, Sheng Qiu, Xiaoxing Xiong
Summary: TUBA1C expression is upregulated in LGG and high expression is associated with poor prognosis, potentially influencing tumor development by regulating tumor-infiltrating cells. TUBA1C may serve as a potential target for immunotherapy.
FRONTIERS IN GENETICS
(2021)
Article
Multidisciplinary Sciences
Derui Yan, Qi Zhao, Zixuan Du, Huijun Li, Ruirui Geng, Wei Yang, Xinyan Zhang, Jianping Cao, Nengjun Yi, Juying Zhou, Zaixiang Tang
Summary: This study aimed to develop an immune-related radiosensitivity gene signature to predict the survival of lower-grade gliomas (LGGs) patients who received radiotherapy. Patients were classified into a radiosensitive (RS) group and a radioresistant (RR) group based on this gene signature, and the RS group showed a higher overall survival rate. The gene signature was specific to radiotherapy and could serve as an independent prognostic indicator. By incorporating this gene signature and other clinical factors, the nomogram model performed well in predicting the survival of LGGs patients after radiotherapy.
SCIENTIFIC REPORTS
(2022)
Article
Biochemistry & Molecular Biology
Xiaoyue Ren, Chao Chang, Teng Qi, Pengyu Yang, Yuanbo Wang, Xiaorui Zhou, Feng Guan, Xiang Li
Summary: Dysregulation of clusterin (CLU) has been found in various cancers, including gliomas. High CLU expression is associated with worse prognosis and higher risk in low-grade glioma patients. CLU is involved in immune status and has correlations with immune cells and immune-related pathways in gliomas. These findings suggest that CLU may serve as a potential biomarker or target in glioma immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Cong Luo, Zhixiong Liu, Wenrui Ye, Fangkun Liu
Summary: This study identified immune infiltrates associated with overall survival in lower grade glioma patients and obtained 44 hub genes to construct an immune infiltration-related signature. The signature showed potential as a prognostic biomarker for glioma patients.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Nanxi Shen, Shu Chen, Dong Liu, Xiangde Min, Qinghai Tan
Summary: This study systematically analyzed the classification, prognostic value, and relationship with tumor microenvironment (TME) of cuproptosis-associated genes (CAGs). Four clusters of CAGs were identified, and their associations with clinical features, prognosis, immune cell infiltration, and chemotherapy sensitivity were observed. The cuproptosis score (Cuscore) was found to be an independent prognostic indicator in lower-grade glioma (LrGG) patients. A high Cuscore was associated with worse prognosis, immune infiltration, and increased tumor mutation burden, as well as with immune checkpoint inhibitors, immunotherapy response, and immune phenotype.
JOURNAL OF GENE MEDICINE
(2023)
Article
Immunology
Junhong Li, Shuxin Zhang, Siliang Chen, Yunbo Yuan, Mingrong Zuo, Tengfei Li, Zhihao Wang, Yanhui Liu
Summary: This study found a relationship between glioma and lipid metabolism and established a risk model based on lipid metabolism-related genes that can effectively predict prognosis in glioma patients. Additionally, the model can stratify patients into different groups with distinct immune characteristics, suggesting that immunotherapy may be beneficial for glioma patients with specific lipid metabolism profiles.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Yongze He, Yuxiang Cai, Jinsheng Liu, Haixia Ding, Xiang Li, Sufang Tian, Zhiqiang Li
Summary: Current treatments for lower-grade glioma (LGG) are not effective in improving survival rates. By studying the role of pyroptosis in tumor progression and occurrence, we identified CASP4 as an effective marker for predicting LGG prognosis. The effects on immune cell infiltration may also provide guidance for future immunotherapy strategies.